Trial reportModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2016
Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.
Trial report in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 222 citations in OpenAlex.
- Trial
- Cribriform and intraductal carcinoma in prostate cancer - implications for risk stratification and therapeutic decision-making.Nature reviews. Urology · 2026Review
- Unsampled large cribriform and intraductal carcinoma and the limits of risk stratification by prostate biopsy.BJU international · 2026Article
- Spatial transcriptomics reveals clonal relationships between intraductal carcinoma and adjacent invasive prostate cancer.Histopathology · 2026Article
- A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer.Discover oncology · 2026Article
- Prognostic value of cribriform pattern and intraductal carcinoma of the prostate after radical prostatectomy: A systematic review and meta-analysis using contemporary consensus recommendations.Prostate cancer and prostatic diseases · 2026Review
- BRCA Testing in Prostate Cancer: A Histopathologist's Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Association Between Cribriform Architecture and Tertiary Gleason Pattern 5 in Prostate Cancer: A Cross-Sectional Study of Radical Prostatectomy Specimens.Journal of clinical medicine · 2026Article
- Cervical Skip Metastases and Extensive Central Venous Thrombosis as the Initial Presentation of High-Grade Prostate Adenocarcinoma With Discordant PI-RADS 3 Findings: A Case Report and Diagnostic Challenge.Clinical case reports · 2026Article
- The evolution of prostate cancer grading: from Gleason score to risk taxonomy and the artificial intelligence revolution.Virchows Archiv : an international journal of pathology · 2026Review
- Comparison of biopsy gleason pattern 4 percentage and length in grade group 2 prostate cancer patients.Virchows Archiv : an international journal of pathology · 2026Article
- Cribriform Tumor Burden in Grade Group 4 Prostate Cancer: A Quantitative Threshold Predicting Lymphovascular Invasion and Metastasis.Journal of clinical medicine · 2026Article
- Association Between Cribriform Architecture and Lymphovascular Invasion in Prostate Cancer.Journal of clinical medicine · 2026Article
- Prostate Cancer: Etiology, Diagnosis, and Treatment.Serican journal of medicine · 2026Article
- Treatment-related changes in the prostate: past, present and future therapies.Histopathology · 2026Review
- Validation of Artificial Intelligence-enhanced Stimulated Raman Histopathology for Intraoperative Margin Assessment During Robot-assisted Radical Prostatectomy: Preliminary Results from the ROBOSPEC Study.European urology open science · 2025Article
- Current grading of prostate cancer.Pathologie (Heidelberg, Germany) · 2025Review
- Cribriform pattern and IDC-P in prostate biopsies: prognostic relevance and reporting in metastatic disease.The journal of pathology. Clinical research · 2025Article
- Determinants of oncologic outcomes in high-grade organ-confined prostate cancer after prostatectomy.Histopathology · 2025Article
- Classification of prostatic adenocarcinoma as favourable/unfavourable histology has high interobserver agreement in prostate needle core biopsies.Histopathology · 2025Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive cribriform and intraductal carcinoma in radical prostatectomy specimens have been associated with an adverse clinical outcome. Our objective was to determine the prognostic value of invasive cribriform and intraductal carcinoma in pre-treatment biopsies on time to disease-specific death. We pathologically revised the diagnostic biopsies of 1031 patients from the first screening round of the European Randomized Study of Screening for Prostate Cancer (1993-2000). Ninety percent of all patients (n=923) had received active treatment, whereas 10% (n=108) had been followed by watchful waiting. The median follow-up was 13 years. Patients who either had invasive cribriform growth pattern or intraductal carcinoma were categorized as CR/IDC+. The outcome was disease-specific survival. Relationships with outcome were analyzed using multivariable Cox regression and log-rank analysis. In total, 486 patients had Gleason score 6 (47%) and 545 had ≥7 (53%). The 15-year disease-specific-survival probabilities were 99% in Gleason score 6 (n=486), 94% in CR/IDC- Gleason score ≥7 (n=356) and 67% in CR/IDC+ Gleason score ≥7 (n=189). CR/IDC- Gleason score 3+4=7 patients did not have statistically different survival probabilities from those with Gleason score 6 (P=0.30), while CR/IDC+ Gleason score 3+4=7 patients did (P<0.001). In multivariable analysis, CR/IDC+ status was independently associated with a poorer disease-specific survival (HR 2.6, 95% CI 1.4-4.8, P=0.002). We conclude that CR/IDC+ status in prostate cancer biopsies is associated with a worse disease-specific survival. Our findings indicate that men with biopsy CR/IDC- Gleason score 3+4=7 prostate cancer could be candidates for active surveillance, as these patients have similar survival probabilities to those with Gleason score 6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.